drugset / Trial / NCT02679573

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

NCT02679573

Phase 3 Completed 860 enrolled Melinta Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of delafloxacin compared to moxifloxacin in the treatment of adult patients with community-acquired pneumonia.

Timeline

Start
2016-12-14
Primary completion
2018-07-31
Completion
2018-08-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Delafloxacin Small molecule 450 mg Intravenous
Comparator Linezolid Other / unclassified 600 mg Intravenous
Comparator Moxifloxacin Small molecule 400 mg Intravenous

Indications